NEW MEDICAL TECHNOLOGIES IN THE REHABILITATION OF PATIENTS WITH CHRONIC VIRAL HEPATITIS C
Keywords:Chronic viral hepatitis C, immunology, pharmacopuncture, Alloplant.
The clinical and immunological evaluation of the treatment of 182 patients with chronic viral hepatitis C with the use of pharmacopuncture with Alloplant biomaterial was carried out. All patients took the drug Phosphogliv as a basic therapy. When assessing the dynamics of the biochemical blood test against the background of pharmacopuncture, a markedly more pronounced decrease in the level of the enzymes alkaline phosphatase, ALT and AST was revealed in comparison with the group receiving only Phosphogliv. All patients had baseline leukopenia and lymphopenia. The analysis of the immunogram parameters revealed that in patients treated with pharmacopuncture with Alloplant biomaterial, there was an increase in the number of white blood cells by 1.6 times, including lymphocytes by 2.2 times compared to the control group. Thus, the study revealed the anti-inflammatory, hepatoprotective and immunoregulatory effects of the acupuncture administration of the biomaterial "Alloplant".
Golovanova EV Treatment of chronic viral hepatitis: achievements and prospects // Experimental and clinical gastroenterology 2012. №6. URL: https://cyberleninka.ru/article/n/lecheniehronicheskih-virusnyh-gepatitov-dostizheniya-iperspektivy
Muldashev E.R., Galiyakhmetov R.F. and other Technologies of tissue transplantation in reflexology and rehabilitation. V All-Russian symposium with international participation Topical issues of tissue andcell transplantation. P. 279 - 280
Nechaeva LS, Malov IV Antiviral therapy of chronic viral hepatitis C at the present stage // Sib. honey. zhurn.(Irkutsk). 2005. No. 7. Url: https://cyberleninka.ru/article/n/protivovirusnayaterapiya-hronicheskogo-virusnogo-gepatita-s-nasovremennom-etape
Ten V.P., Muldashev E.R. et al. Acupuncture therapy with the Alloplant biomaterial // Modern science-intensive technology. - 2005. - No. 8. - P. 104-105
Uchaikin V.F., Kovalev O.B. The use of phosphogliv in acute and chronic viral hepatitis in children // Children's infections. 2006. No. 1. URL: https://cyberleninka.ru/article/n/primeneniefosfogliva-pri-ostryh-i-hronicheskih-virusnyhgepatitah-u-detey (date accessed: 17.08.2019).
Fazylov V. Kh., Enaleeva D. Sh.,Gaifullina EG et al. Antiviral therapy of chronic viral hepatitis in a hepatological office // Practical medicine. 2005. # 1 (10).URL: https: //cyberleninka.ru/article/n/protivovirusnaya -terapiya-hronicheskih-virusnyh-gepatitov-vusloviyah-gepatologicheskogo-kabineta
Yakovleva O.A. , Semenchuk S.A. and others. New aspects of the use of a hepatoprotector based on phospholipids and glycyrrhizic acid Rational pharmacotherapy 4 (37) 2015. - С.10-13
Hosseinzaden H., Nassiri-Asl M.Pharmacological Effects of Glycyrrhiza spp. and Its Bioactive Constituents: Update and Review. Phytother Res. 2015 Dec; 29 (12): 1868-86. doi: 10.1002 / ptr.5487. Epub 2015 Oct 13.
Krawitt E. L., Ashikaga T., Gordon S. R. et al. Peginterferon alfa-2b and ribavirin for treatment refractory chronic hepatitis C // J. Hepatol. - 2005. - Vol. 43.- P. 243-249.
Tarao K., Rino Y., Ohkawa S. et al. Association between high serum alanine aminotransferase levels and more rapid development and higher rate of incidence of hepatocellular carcinoma in patients with hepatitis C-virus associated cirrhosis. Cancer August 15,1999; 86: 589-95.
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
A work licensed in this way allows the following:
1. The freedom to use and perform the work: The licensee must be allowed to make any use, private or public, of the work.
2. The freedom to study the work and apply the information: The licensee must be allowed to examine the work and to use the knowledge gained from the work in any way. The license may not, for example, restrict "reverse engineering."
2. The freedom to redistribute copies: Copies may be sold, swapped or given away for free, in the same form as the original.